HK1020741A1 - 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase - Google Patents

3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Info

Publication number
HK1020741A1
HK1020741A1 HK99105993A HK99105993A HK1020741A1 HK 1020741 A1 HK1020741 A1 HK 1020741A1 HK 99105993 A HK99105993 A HK 99105993A HK 99105993 A HK99105993 A HK 99105993A HK 1020741 A1 HK1020741 A1 HK 1020741A1
Authority
HK
Hong Kong
Prior art keywords
mercaptoacetylamino
oxo
inhibitors
substituted
matrix metalloproteinase
Prior art date
Application number
HK99105993A
Other languages
English (en)
Inventor
Alan M Warshawsky
Gary A Flynn
Meena V Patel
Douglas W Beight
Joseph P Burkhart
Jiu-Tsair Tsay
Michael J Janusz
Jian Shen
Ramalinga M Dharanipragada
Original Assignee
Aventis Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceutical Inc filed Critical Aventis Pharmaceutical Inc
Publication of HK1020741A1 publication Critical patent/HK1020741A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK99105993A 1996-09-19 1999-12-21 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase HK1020741A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (1)

Publication Number Publication Date
HK1020741A1 true HK1020741A1 (en) 2000-05-19

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105993A HK1020741A1 (en) 1996-09-19 1999-12-21 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Country Status (21)

Country Link
EP (1) EP0928291B1 (xx)
JP (1) JP3962091B2 (xx)
KR (1) KR100545460B1 (xx)
CN (1) CN1150205C (xx)
AR (1) AR009363A1 (xx)
AT (1) ATE229034T1 (xx)
AU (1) AU718055B2 (xx)
BR (1) BR9713207A (xx)
CA (1) CA2266759C (xx)
DE (1) DE69717647T2 (xx)
DK (1) DK0928291T3 (xx)
ES (1) ES2184126T3 (xx)
HK (1) HK1020741A1 (xx)
HU (1) HUP9904165A3 (xx)
IL (2) IL129035A0 (xx)
NO (1) NO991316L (xx)
NZ (1) NZ334490A (xx)
PT (1) PT928291E (xx)
TW (1) TW445262B (xx)
WO (1) WO1998012211A1 (xx)
ZA (1) ZA978307B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
WO2000040553A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CN1416346A (zh) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
EP3630969B1 (en) 2017-05-31 2023-06-07 BRAIN Biotech AG Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2586942B2 (ja) * 1987-03-17 1997-03-05 リサーチ コーポレーシヨン テクノロジーズ インコーポレーテツド 哺乳動物コラゲナーゼの合成阻止剤
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
WO1996011209A1 (en) * 1994-10-05 1996-04-18 Chiroscience Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
IL129035A (en) 2006-12-10
JP2001501926A (ja) 2001-02-13
DE69717647T2 (de) 2003-09-25
EP0928291B1 (en) 2002-12-04
JP3962091B2 (ja) 2007-08-22
ZA978307B (en) 1998-03-19
CA2266759C (en) 2004-10-26
CA2266759A1 (en) 1998-03-26
AU3827897A (en) 1998-04-14
DK0928291T3 (da) 2003-03-17
TW445262B (en) 2001-07-11
ATE229034T1 (de) 2002-12-15
CN1150205C (zh) 2004-05-19
NO991316D0 (no) 1999-03-18
WO1998012211A1 (en) 1998-03-26
AU718055B2 (en) 2000-04-06
AR009363A1 (es) 2000-04-12
KR100545460B1 (ko) 2006-01-24
HUP9904165A2 (hu) 2000-03-28
BR9713207A (pt) 2000-04-04
EP0928291A1 (en) 1999-07-14
PT928291E (pt) 2003-03-31
HUP9904165A3 (en) 2002-01-28
NZ334490A (en) 2000-08-25
KR20000036246A (ko) 2000-06-26
ES2184126T3 (es) 2003-04-01
NO991316L (no) 1999-05-18
DE69717647D1 (de) 2003-01-16
IL129035A0 (en) 2000-02-17
CN1234039A (zh) 1999-11-03

Similar Documents

Publication Publication Date Title
IL130111A0 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
PL331854A1 (en) Phosphinamides as inhibitors of metaloprotease matrix
AU8875798A (en) Meta-benzamidine derivatives as serin protease inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
IL128662A0 (en) Heterocyclic metalloprotease inhibitors
IL128664A0 (en) Heterocyclic metalloprotease inhibitors
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
AU8858398A (en) Matrix metalloproteinase inhibitors
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
AU3342297A (en) Matrix metalloproteinase inhibitors
HUP9904664A3 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
ZA975986B (en) N-alkoxyadenine derivatives acting as cytokine inhibitors.
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
HRP970247A2 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
AU5128298A (en) Metalloproteinase inhibitors
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
AU9747098A (en) Aporphinoid matrix metalloproteinase inhibitors
AU7066398A (en) Novel use of matrix metalloproteinase inhibitors
SI0928291T1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
SI1001930T1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
GB9627016D0 (en) Novel use of matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120804